“Long COVID Treatment: Evidence-Based Options and What Actually Helps”

Post-COVID long COVID treatment works by targeting symptom clusters, because no drug is FDA approved for long COVID (also called post-COVID condition or PASC) as of 2025. The options with the most support are pacing for post-exertional malaise, low-dose naltrexone (LDN, 1.5 to 4.5 mg daily), H1 and H2 antihistamines for mast cell symptoms, and hyperbaric oxygen therapy (HBOT), which improved cognition and energy in a 2022 sham-controlled trial of 73 patients after 40 sessions.

What Is Post-COVID Condition, and How Is It Treated?

Post-COVID condition (PCC) is the World Health Organization's term for long COVID: symptoms that usually start within 3 months of a COVID-19 infection and last at least 2 months. Other names for the same illness include post-acute sequelae of SARS-CoV-2 infection (PASC), post-COVID-19 syndrome and long-haul COVID. In US medical records it is coded as ICD-10 U09.9.

According to the WHO post COVID-19 condition fact sheet, global estimates suggest about 6 in 100 people with COVID-19 develop the condition. The most common symptoms are fatigue, shortness of breath, brain fog, sleep problems, palpitations and a crash after exertion. Our long COVID condition overview covers the full symptom picture, and the post-COVID symptom checklist helps match symptoms to clusters.

Treatment for post-COVID long COVID follows one principle: identify the dominant symptom cluster, then treat that cluster. WHO guidance describes this as self-management support, medication for symptom relief and referral to rehabilitation. Integrative and regenerative clinics add options such as HBOT, NAD+ infusions and peptides, which have a weaker evidence base and are usually paid out of pocket.

Why Long COVID Treatment Is So Complicated

Long COVID is not one disease. It is a collection of overlapping syndromes, and what drives symptoms in one person may be completely different from what drives them in another. Some patients have viral persistence, meaning fragments of SARS-CoV-2 are still detectable months later. Others have autoimmune dysregulation, microbiome disruption, reactivated latent viruses like Epstein-Barr, or autonomic nervous system dysfunction. Many have a combination [1].

This is why treatments that help some people do nothing for others. It also explains why clinical trials have been difficult to run. The NIH’s RECOVER initiative, the largest long COVID research program ever funded, has faced criticism for being slow to produce actionable treatment data. As of 2025, no drug is formally approved specifically for Long COVID, though several are used off-label with good rationale [2].

The practical approach that most Long COVID clinics now take is to identify which subtype or symptom cluster a patient fits, then target treatment accordingly. That framework guides what follows here.

Long COVID Treatment Options by Symptom Cluster

Most long COVID clinicians match treatment to the symptom cluster that limits a patient most. The table below summarizes the options covered in the sections that follow, with the dose or protocol the evidence describes and an honest read of how strong that evidence is.

Every option in this table is off label for long COVID. Several, including HBOT, NAD+ infusions and compounded LDN, are usually cash pay, so cost and access shape the plan as much as the evidence does.

Medications With Evidence Behind Them

Low-Dose Naltrexone (LDN)

Naltrexone at standard doses (50mg) blocks opioid receptors to treat addiction. At low doses, typically 1.5 to 4.5mg per day, it has a completely different mechanism. LDN appears to modulate microglial activation, reduce neuroinflammation, and normalize immune function. For Long COVID patients with fatigue, pain, and brain fog, a number of small trials and large patient surveys show meaningful benefit [3].

A 2023 survey of over 1,000 Long COVID patients found LDN was one of the most consistently helpful medications reported, with around 74% of users noting some improvement. It is well-tolerated, inexpensive, and available through compounding pharmacies. The main downside is that clinical trial data is still limited compared to the volume of patient-reported benefit.

Antihistamines

There is a significant subset of Long COVID patients who have elevated mast cell activity, sometimes meeting criteria for mast cell activation syndrome (MCAS). Mast cells release histamine and other mediators that can cause widespread symptoms including fatigue, brain fog, flushing, GI distress, and palpitations. Combining an H1 blocker (like fexofenadine or cetirizine) with an H2 blocker (like famotidine) has helped many patients in this group substantially [4].

Famotidine specifically has received attention beyond just histamine blockade. It appears to have anti-viral properties and has been studied as a standalone treatment for COVID-19 and Long COVID symptoms at doses of 80 to 160mg per day. A small randomized trial showed improvement in multiple Long COVID symptom domains [5].

SSRIs and SNRIs

Antidepressants sound like an odd choice for what many patients correctly identify as a physical illness, but the rationale here is biological, not psychiatric. SSRIs inhibit platelet aggregation, which may address the microclotting that some researchers believe contributes to Long COVID. Fluvoxamine also has sigma-1 receptor activity that may reduce inflammation. The TOGETHER trial found fluvoxamine reduced COVID-19 severity, and similar mechanisms may apply in the chronic phase [6].

For patients whose Long COVID features include POTS (postural orthostatic tachycardia syndrome), low-dose SSRIs can help regulate autonomic function. They are not appropriate for everyone, but for certain presentations they represent a reasonable option.

Anticoagulants and Platelet Inhibitors

Microclot theory, developed primarily by South African researchers Resia Pretorius and Douglas Kell, proposes that SARS-CoV-2 triggers the formation of tiny fibrin clots resistant to normal breakdown. These microclots may impair oxygen delivery at the capillary level, explaining symptoms like fatigue and breathlessness even when standard lung tests look normal [7].

Some clinicians are trialing low-dose anticoagulants or antiplatelet regimens based on this hypothesis. Early case series from South Africa showed promising results with triple therapy including aspirin, clopidogrel, and apixaban. This approach carries bleeding risk and is not standard care, but the mechanistic basis is solid enough that several trials are underway.

Antivirals: What the Paxlovid Trials Found

Viral persistence led researchers to test longer antiviral courses for established long COVID. In the STOP-PASC randomized clinical trial at Stanford University, Geng and colleagues (2024) gave 155 adults 15 days of nirmatrelvir-ritonavir (Paxlovid) or placebo and found no statistically significant difference in core symptoms, as reported in JAMA Internal Medicine [15].

That result does not close the question for every subtype, and other antiviral trials, including those run under the NIH RECOVER initiative, are testing different durations and patient groups. For now, antivirals are not a standard long COVID treatment outside a clinical trial.

Hyperbaric Oxygen Therapy

Among all the non-drug interventions studied, HBOT has the strongest clinical trial data. A randomized, double-blind, sham-controlled trial from Israel by Zilberman-Itskovich, Efrati and colleagues, published in Scientific Reports in 2022, enrolled 73 Long COVID patients and found that 40 sessions of HBOT at 2 atmospheres with 100% oxygen produced significant improvements in cognitive function, energy, sleep, pain, and psychiatric symptoms compared to sham treatment [8].

The proposed mechanisms are multiple. Hyperbaric oxygen promotes neuroplasticity and angiogenesis. It reduces neuroinflammation. It enhances mitochondrial function. It may help clear microclots. For a condition with so many potential drivers, an intervention that addresses several simultaneously has obvious appeal.

The practical challenge is cost and access. A full protocol typically involves 40 to 60 sessions of 60 to 90 minutes each. Depending on location, this can run $10,000 to $25,000 out of pocket. Not all HBOT facilities offer the specific protocols used in trials. That said, for patients with significant cognitive or functional impairment, the trial data is strong enough that it warrants serious consideration.

Is HBOT approved for long COVID?

HBOT is not FDA cleared for long COVID, so insurers rarely cover it for this use. The FDA and the Undersea and Hyperbaric Medical Society (UHMS) recognize a short list of indications such as decompression sickness, carbon monoxide poisoning and diabetic wound healing, which our overview of FDA cleared HBOT indications lists in full. Long COVID protocols are off label and cash pay.

The trial protocol used a hard-shell chamber at 2 atmospheres absolute (ATA) with medical supervision, which is different from the 1.3 ATA soft chambers sold for home use. Before booking, ask a clinic which pressure, oxygen concentration and session count it uses. The hyperbaric oxygen therapy treatment guide explains the mechanism and risks, the HBOT for long COVID deep dive walks through the trial data, and you can compare facilities on the national list of HBOT clinics.

NAD+ Therapy

NAD+ (nicotinamide adenine dinucleotide) is central to mitochondrial energy production and cellular repair. SARS-CoV-2 infection appears to deplete NAD+ through multiple mechanisms, including activation of PARP enzymes and CD38, both of which consume NAD+ in large quantities [9]. The resulting energy deficit at the cellular level may explain the profound fatigue that defines many Long COVID cases.

IV NAD+ delivers the molecule directly into circulation, bypassing digestive conversion and achieving much higher plasma levels than oral precursors. Clinically, many Long COVID patients report substantial energy improvements with IV NAD+ protocols, typically 3 to 10 sessions of 500 to 1000mg delivered slowly over several hours. Oral precursors like NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are less potent but offer a maintenance option.

Clinical trial data on NAD+ specifically for Long COVID is still emerging. The mechanistic case is strong, and infusions are generally well tolerated, although flushing, nausea and chest tightness are common when the drip runs too fast. Most regenerative clinics offering Long COVID protocols include NAD+ IV as a core component, and the NAD+ IV therapy guide covers dosing and what a session involves. Clinics that offer it are listed on the NAD+ IV therapy clinic hub.

Peptide Therapies

Peptide therapies are gaining traction in Long COVID treatment, particularly for immune dysregulation and tissue repair. Several peptides have specific relevance here.

BPC-157 (Body Protection Compound 157) has extensive animal data showing anti-inflammatory effects, gut mucosal healing, and neuroprotective properties. Given that Long COVID frequently involves gut dysbiosis and neurological symptoms, BPC-157 is being used by integrative clinicians. Human trial data is limited, and the FDA has listed BPC-157 among bulk substances it says may raise significant safety risks in compounding, which restricts access through US compounding pharmacies [10].

Thymosin alpha-1 (Thymalfasin) is a thymic peptide that modulates immune function, particularly T-cell activity. It is approved in several countries for hepatitis and is being studied for Long COVID given that immune exhaustion and dysregulation are well-documented features of the condition. Some clinics are using it as part of immune reconditioning protocols.

Selank and Semax, nootropic peptides developed in Russia, have shown anxiolytic, anti-inflammatory, and cognitive-enhancing properties in animal and some human studies. They are being used off-label for the neurological and psychiatric symptoms of Long COVID.

None of these peptides is FDA approved for long COVID, and product quality varies between suppliers. The peptide therapy treatment guide explains how prescribing and sourcing work, and the thymosin alpha-1 explainer covers that peptide's immune research in more detail.

Pacing and Post-Exertional Malaise Management

For patients whose Long COVID resembles ME/CFS, pacing is arguably the most important intervention available, and the most commonly given wrong advice is the opposite: graded exercise therapy (GET). Multiple studies have now shown that GET worsens outcomes in ME/CFS and in Long COVID patients with post-exertional malaise (PEM). PEM means that physical or cognitive exertion causes a disproportionate crash that can last days [11].

The UK's NICE guideline on ME/CFS (NG206, 2021) states that graded exercise therapy should not be offered, and the Mayo Clinic Proceedings consensus by Bateman and colleagues (2021) puts activity management at the center of care [11], [14]. The chronic fatigue syndrome condition page and the ME/CFS treatment guide cover the overlap in more depth.

Heart rate monitoring is a practical tool for staying within aerobic limits. Many patients use a threshold of 60% of their heart rate reserve or subtract 15 from their anaerobic threshold. Staying below that limit during all activity, including walking and cognitive work, prevents crashes and allows gradual recovery.

This is not rest forever. It is structured activity management that gives the nervous system a chance to stabilize. Over months, patients who pace well often find their envelope expanding.

Gut Health and Microbiome Interventions

The gut-immune connection in Long COVID is well-documented. Studies using gut microbiome sequencing show that Long COVID patients have distinct dysbiosis patterns compared to people who recovered fully, with depletion of beneficial species like Faecalibacterium prausnitzii and Bifidobacterium [12]. Gut permeability appears elevated, allowing bacterial products to enter circulation and drive systemic inflammation.

Targeted probiotic interventions, particularly those including Lactobacillus rhamnosus and specific Bifidobacterium strains, have shown promise in reducing Long COVID symptom burden in early trials. Dietary approaches supporting microbiome diversity, reducing processed food, and increasing fermented food intake are being studied as complementary approaches.

Emerging Interventions Under Investigation

Several other treatments are in earlier stages of investigation. Baricitinib, a JAK inhibitor approved for rheumatoid arthritis, is being trialed based on its ability to reduce cytokine signaling. Metformin showed a 40% reduction in Long COVID incidence when used during acute infection in a trial published in The Lancet Infectious Diseases in 2023 [13], raising questions about its role in established Long COVID. Ozone therapy is used in some integrative clinics for its proposed effects on oxygen delivery and viral load reduction, though clinical trial data remains limited.

Stellate ganglion blocks, an anesthetic procedure targeting the sympathetic nervous system, are being studied for Long COVID patients with POTS and hyperadrenergic presentations. Early results from small case series are promising, particularly for autonomic symptoms and brain fog. The POTS treatment guide covers the standard first steps, such as fluids, salt and compression, that usually come before a procedure.

Who Treats Long COVID?

Long COVID is usually managed by a primary care physician who coordinates specialists for each symptom cluster. Many academic medical centers run dedicated post-COVID clinics, and integrative and functional medicine physicians run long COVID programs in private practice.

• Physical medicine and rehabilitation physicians (physiatrists) lead many post-COVID clinics and design pacing plans.
• Cardiologists and autonomic specialists evaluate POTS and other forms of dysautonomia with tilt table testing.
• Allergists and immunologists assess mast cell activation syndrome and guide antihistamine protocols.
• Neurologists and neuropsychologists assess brain fog, headache and cognitive change.
• Pulmonologists investigate persistent shortness of breath when standard lung tests are abnormal.
• Hyperbaric medicine physicians, often UHMS trained, supervise HBOT protocols.

Ask any clinician how many long COVID patients they see, which symptom clusters they treat, and how they measure progress. The dysautonomia treatment guide and the MCAS, POTS and EDS overlap explainer help when those clusters lead.

Building a Treatment Plan

The most effective approach to Long COVID treatment is systematic. Start with symptom clustering: which systems are most affected? Cardiovascular, neurological, metabolic, immunological, or some combination? This guides what to prioritize first.

Most Long COVID specialists recommend addressing foundational issues first: sleep quality, orthostatic intolerance (if present), and pacing to prevent PEM crashes. On top of that foundation, targeted interventions can be layered based on dominant symptom patterns.

1. Rule out other causes with standard testing, including blood counts, thyroid function, iron studies and a heart and lung workup where symptoms point there.
2. Name the dominant symptom cluster: fatigue and PEM, brain fog, autonomic symptoms, mast cell symptoms, or breathlessness.
3. Stabilize the foundation with pacing, sleep and, for orthostatic intolerance, fluids and salt.
4. Add one targeted treatment at a time, such as LDN or antihistamines, so you can tell what helps.
5. Track symptoms and heart rate for several weeks before judging a change.
6. Consider cash pay options such as HBOT or NAD+ infusions only with clear protocols and a clinician who explains the evidence.
7. National Institute for Health and Care Excellence. “Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management.” NICE guideline NG206. 2021. https://www.nice.org.uk/guidance/ng206
8. Geng LN, Bonilla H, Hedlin H, et al. “Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.” JAMA Intern Med. 2024;184(9):1024-1034. https://pubmed.ncbi.nlm.nih.gov/38848477/

Working with a physician who understands Long COVID and is willing to consider off-label options is significantly better than waiting for a single approved treatment that may not exist for years. The field is moving fast. What was considered fringe in 2021 is now discussed in mainstream journals, and the treatment options available today are meaningfully better than they were even two years ago.

How to Find a Long COVID Clinic in the Directory

Regenerated.com lists clinics by treatment, so the most direct route is the treatment you want to explore: the HBOT clinic directory, the IV therapy clinic list for NAD+ and vitamin infusions, or the peptide therapy clinic hub. The long COVID treatment guide explains which of these treatments fit which symptoms.

Listing order on Regenerated.com is not paid ranking. Featured slots are clearly labeled and capped on every page. Verified means a clinic completed credential checks, not that it paid. Regenerated.com is free for patients, and inclusion in the directory is not an endorsement. The guide to Featured, Verified and organic listings explains each label.

Frequently asked questions

What is the most effective post-COVID long COVID treatment?

No single treatment works for everyone, because long COVID has several drivers. The most consistent results come from matching treatment to the main symptom cluster: pacing for post-exertional malaise, low-dose naltrexone for fatigue and pain, H1 plus H2 antihistamines for mast cell symptoms, and hyperbaric oxygen therapy for cognitive symptoms, which improved brain fog and energy in a 2022 sham-controlled trial. Most patients combine two or three approaches under one coordinating clinician.

Is there an FDA approved medication for long COVID?

No medication is FDA approved specifically for long COVID as of 2025. Every drug used for it, including low-dose naltrexone, famotidine, cetirizine, fluvoxamine and other SSRIs, is prescribed off label for a symptom it already treats in other conditions. The NIH RECOVER initiative and other research groups are running randomized trials, and the STOP-PASC trial (2024) found that a 15 day course of Paxlovid did not significantly improve symptoms.

How long does long COVID treatment take to work?

Most long COVID treatments are judged over weeks to months rather than days. In the Israeli HBOT trial, patients completed 40 sessions over about two months before outcomes were measured. Clinicians usually give low-dose naltrexone and antihistamine protocols several weeks at a stable dose before deciding whether they help. Pacing works more slowly still: many patients see their activity envelope expand over months, which is why symptom and heart rate tracking matters.

Does insurance cover long COVID treatment?

Insurance usually covers the conventional parts of long COVID care, such as doctor visits, testing, generic prescriptions, physical therapy and referrals to post-COVID clinics. It rarely covers hyperbaric oxygen therapy, NAD+ infusions, peptides or compounded low-dose naltrexone for this use, because they are off label. An HBOT protocol of 40 to 60 sessions can cost $10,000 to $25,000 out of pocket, so ask any clinic for a written protocol and total price first.

Should I exercise to recover from long COVID?

Exercise helps some long COVID patients, but it harms those with post-exertional malaise, where effort triggers a crash that can last days. For that group, pacing comes first: keeping activity below roughly 60% of heart rate reserve and resting before symptoms flare. NICE guidance (2021) advises against graded exercise therapy for ME/CFS. Patients without post-exertional malaise can often rebuild fitness gradually with a rehabilitation professional who adjusts the plan to symptoms.

Can hyperbaric oxygen therapy help long COVID brain fog?

Hyperbaric oxygen therapy improved cognitive function in a 2022 randomized, double-blind, sham-controlled trial of 73 long COVID patients by Zilberman-Itskovich, Efrati and colleagues. Participants received 40 sessions at 2 atmospheres absolute with 100% oxygen, and brain imaging in a companion study showed changes in connectivity. The evidence comes mainly from one research group, HBOT is off label for long COVID, and it requires a medically supervised hard-shell chamber rather than a home soft chamber.

Related Reading

• Long COVID Symptoms: The Complete Guide to Post-COVID Syndrome
• Post-COVID Fatigue: Why It Happens and How to Recover
• Long COVID Recovery: Timeline, Strategies, and When to Seek Help
• Long COVID Brain Fog Treatment
• Hyperbaric Oxygen Therapy: Benefits, Risks, and What to Expect
• NAD+ IV Therapy: What It Does and Who It Helps
• MCAS Treatment: Managing Mast Cell Activation Syndrome

Sources

1. Davis HE, McCorkell L, Vogel JM, Topol EJ. “Long COVID: major findings, mechanisms and recommendations.” Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2 ↩
2. Kedor C, Freitag H, Meyer-Arndt L, et al. “A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with its clinical course.” Lancet EClinicalMedicine. 2022;51:101549. doi:10.1016/j.eclinm.2022.101549 ↩
3. Younger J, Parkitny L, McLain D. “The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.” Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2 ↩
4. Afrin LB, Weinstock LB, Molderings GJ. “COVID-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome.” Int J Infect Dis. 2020;100:327-332. doi:10.1016/j.ijid.2020.09.016 ↩
5. Janowitz T, Gablenz E, Pattinson D, et al. “Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients.” Gut. 2020;69(9):1592-1597. doi:10.1136/gutjnl-2020-321852 ↩
6. Lenze EJ, Mattar C, Zorumski CF, et al. “Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19.” JAMA. 2020;324(22):2292-2300. doi:10.1001/jama.2020.22760 ↩
7. Pretorius E, Venter C, Laubscher GJ, et al. “Prevalence of readily detected amyloid blood clots in unvaccinated, vaccinated and COVID-19 patients.” Cardiovasc Diabetol. 2021;20(1):172. doi:10.1186/s12933-021-01359-7 ↩
8. Zilberman-Itskovich S, Catalogna M, Sasson E, et al. “Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial.” Sci Rep. 2022;12(1):11252. doi:10.1038/s41598-022-15565-0 ↩
9. Minhas PS, Liu L, Moon PK, et al. “Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation.” Nat Immunol. 2019;20(1):50-63. doi:10.1038/s41590-018-0255-3 ↩
10. Sikiric P, Seiwerth S, Rucman R, et al. “Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157.” Curr Med Chem. 2012;19(1):126-132. doi:10.2174/092986712803414004 ↩
11. Bateman L, Bested AC, Bonilla H, et al. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management.” Mayo Clin Proc. 2021;96(11):2861-2878. doi:10.1016/j.mayocp.2021.07.004 ↩
12. Liu Q, Mak JWY, Su Q, et al. “Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome.” Gut. 2022;71(3):544-552. doi:10.1136/gutjnl-2021-325989 ↩
13. Bramante CT, Buse JB, Liebovitz DM, et al. “Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.” Lancet Infect Dis. 2023;23(10):1119-1129. doi:10.1016/S1473-3099(23)00299-2 ↩
14. National Institute for Health and Care Excellence. “Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management.” NICE guideline NG206. 2021. https://www.nice.org.uk/guidance/ng206 ↩
15. Geng LN, Bonilla H, Hedlin H, et al. “Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.” JAMA Intern Med. 2024;184(9):1024-1034. https://pubmed.ncbi.nlm.nih.gov/38848477/ ↩